Fourteen (14/199, 7%) patients with TCR MM were re-treated with an anti-CD38 mAb in combination with either an IMiD or PI in next line of therapy after progression on the index regimen, and 8 patients achieved at least a partial response (ORR 57%, 8/14 patients). The gene discussed is CD38; the disease is Miyoshi myopathy.